Therefore, we launched into a line of investigation utilizing preclinical models to test the hypothesis that HuR drives aggressive PDA biology, and may be targeted as a novel treatment strategy for PDA. The gene discussed is ELAVL1; the disease is Patent ductus arteriosus.